Cultured Host Cells* E

Total Page:16

File Type:pdf, Size:1020Kb

Cultured Host Cells* E 189 ENHANCEMENT BY LYSOZYME AND HYALURONIDASE OF THE PENETRATION BY TOXOPLASMA GONDII INTO CULTURED HOST CELLS* E. LYCKE, EBBA LUND AND 0. STRANNEGARD From the Municipal Virological Laboratory, Gothenburg, Sweden Received for publication August 17, 1964 LYSOZYME, a basic polypeptide, is lytic for certain strains of bacteria and is antivirally active. It occurs in tissues and body fluids, e.g. in serum, and is supposed to be of importance in the mechanism of native immunity. In connection with a study on the influence of different serum factors on the infectivity of toxoplasma parasites for cultured cells (Lycke, Lund, Strannegard and Falsen, 1964) the effect of crystallized egg-white lysozyme on the parasites was examined. No antiparasitic activity of lysozyme could be demonstrated but in the presence of lysozyme the number of parasites which penetrated the host cells was increased. A similar enhancement of the penetration of parasites was demonstrable with another mucolytic enzyme tested, hyaluronidase. The present report describes and discusses the penetration-promoting effects exerted by lysozyme and hyaluro- nidase. MATERIAL AND METHOD The parasite suspensions. The RH strain of Toxoplasma gondii was used. The prepara- tion of suspensions of toxoplasma parasites from mouse peritoneal exudate has been described previously (Lycke and Lund, 1964a). The suspensions employed contained 4-8 x 106 to 1-44 x 107 parasites per ml. If not otherwise stated, the suspending medium was the same as the cell culture medium described below. The HeLa cell cultures.-HeLa cells were cultured as monolayer cultures in Gey chambers. The medium employed consisted of 0 5 per cent lactalbumin hydrolysate in Hanks' salt solution, to which 20 per cent dye test negative human serum, 100 i.u. penicillin and 100 pg. streptomycin per ml. were added. The culture technique and the standardization of the cultures have been reported (Lycke and Lund, 1964a, b). The cell culture test.-The parasite suspension was mixed with an equally large volume of a solution in Hanks' buffer of the compound to be tested. A set of three cultures was inoculated with the mixture, each culture receiving 0 4 ml. as replacement for the culture medium. The cultures were incubated at 370 for 19 hr. unless otherwise stated. At the readings, the relation between the number of parasites in the inoculum having penetrated the host cells and the number of host cells exposed was determined. The figure expressing this relation is referred to as the relative number of infective units (RNIU). The accuracy of the RNIU determinations, the relation of the RNIU to the concentration of infective parasites and the use of the cell culture method for determination of the growth rate of parasites have been described previously (Lycke and Lund, 1964b). The compounds tested.-The lysozyme used was an egg-white preparation. (Muramidase twice crystallized, Worthington Biochem. Corp. Freehold, New Jersey, U.S.A.). The other compounds tested were obtained from the following sources: Hyaluronidase: Nutritional Biochem. Corp. Cleveland, Ohio, U.S.A.; Hyaluronic acid: A.B. Leo, Halsingborg, Sweden; Polymyxin: Novo Industri A/S, Copenhagen, Denmark; Protamine sulphate: L. Light * This study was supported by a PHS research grant, AI 05074-02, from the National Institute of Allergy and Infectious Diseases, Public Health Service, U.S.A. 190 E. LYCKE, EBBA LUND AND 0. STRANNEGARD and Co. Ltd., Colnbrook, England; Sodium ethylenediamine tetra-acetate (EDTA), Titriplex: E. Merck AG, Darmstadt, Germany; RDE (Receptor destroying enzyme) Vibrio cholera filtrate: N. V. Philips-Duphar, Amsterdam, Holland; fl-amylase: L. Light and Co. Ltd., Colnbrook, England; Phospholipase: Venom (Crotateus Adamanteus), Sigma Chem. Co., St. Louis, U.S.A. The absorption with bentonite.-Bentonite was employed for the removal of lysozyme. The method used for absorption was in principle that of Myrvik and Weiser (1955). Four mg. bentonite washed in Hanks' solution were employed for the absorption of 1 mg. lysozyme. EXPERIMENTS The penetration by toxoplasma in the presence of lysozyMe.-Lysozyme was added to suspensions of toxoplasma parasites which were tested in cell cultures. It was found that in the presence of lysozyme the number of parasites which penetrated the host cells was considerably increased (Fig. 1). The use of 1 mg. 100 _ 80 - 60 -4 40 - 20 - 00 1 3 6 Hours FIG. 1. The effect of lysozyme on penetration by toxoplasma into HeLa cells. The relative number of infective units, (RNIU) is plotted against the incubation time after inoculation of the cell cultures with parasites. The stippled curve refers to the results obtained with cultures to which lysozyme (1 mg./ml.) was added. The fully drawn curve shows the results obtained with cultures without lysozyme. lysozyme per ml. of the parasite suspending fluid resulted in 20-60 per cent larger RNIU values than were obtained with suspensions without lysozyme. This effect was demonstrable whether or not the suspensions contained serum in addition to lysozyme (Table I). TABLE I.-Penetration by Toxoplasma of HeLa Cells in the Presence of Lysozyme (1 mrg./ml.) Parasite suspending fluid RNIU Hanks' solution . 55* 2 Hanks' solution + lysozyme . 75 * 7 Normal human serum . 62- 7 Normal human serum + lysozyme 98- 4 PENETRATION OF TOXOPLASMA INTO CULTURED CELLS 191 The relation of the penetration-promoting effect to the concentration of lyso- zyme used is illustrated by Fig. 2. The concentrations of lysozyme tested ranged from 0.001-10 mg. per ml. of the parasite suspension. In the figure, the concen- trations of lysozyme are plotted against the mean values of the RNIU in 4 experi- ments. Concentrations of 0.01 mg. per ml. or less caused no effect on the penetra- 0 01 1 0 10.0 mg. ml. FIlo. 2. The effect of different concentrations of lysozymne on penetration by toxoplasma into HeLa cells. The concentration of lysozyme (mg./ml. of inoculated parasite suspension) is l)lotted against the relative number of infective units (RNIU). tion, but when amounts larger than 0*01 mg. were tested the RNIU increased proportionately to the concentration of lysozyme. Absorption with bentonite inhibited the penetration-promoting effect of lysozyme (Table II). TABLE II.-Inhibition of the Penetration-promoting Effect of Lysozyme by Absorption with Bentonite Parasite suspending fluid RNIU Cell culture medium . 37 * 9 Cell culture medium + lysozyme 54 8 Cell culture medium + lysozyme, absorbed with bentonite . 39 :2 The penetration-promoting effect of lysozyme supplemented with protamine sul- phate, EDTA or polymyxin.-Like lysozyme, protamine sulphate is a basic protein and has in certain cases a similar effect (Pontieri, Imperato and Cavallo (1962). Sodium ethylenediamine tetra-acetate (EDTA) and polymyxin are known to influence the action of lysozyme on the cell walls of bacteria (Repaske, 1956, 1958; Warren, Gray and Yurchenco, 1954). In a series of experiments the effect of these compounds on the penetration-promoting activity oflysozyme was studied. 192 E. LYCKE, EBBA LUND AND 0. STRANNEGARD Lysozyme, protamine sulphate and polymyxin were each used in a concentration of 1-0 mg. per ml. of the parasite suspension inoculated into the cultures. EDTA was employed in a concentration of 0.001 M. A serum-free suspension of parasites was used. The results obtained are listed in Table III. TABLE III.-The Effect on the Penetration by Toxoplasma of HeLa Cells when Adding Lysozyme, Protamine Sulphate, EDTA or Polymyxin Compounds tested RNIU Protamine sulphate 51*9 Protamine sulphate + lysozyme 61-0 Lysozyme . 80- 2 Control. No additive 51 * 6 EDTA . 54-1 EDTA + lysozyme . 62 * 8 Lysozyme . 69- 4 Control. No additive . 51 2 Polymyxin. a5 1 Polymyxin + lysozyme 68- 7 Lysozyme 66- 7 Control. No additive . 538 None of the three compounds tested seemed per se to affect the penetration of toxoplasma or to enhance the penetration-promoting effect of lysozyme. On the other hand the use of protamine sulphate together with lysozyme seemed to inhibit the effect of the enzyme. The effect of hyaluronidase on the penetration of toxoplasma parasites.-Like lysozyme hyaluronidase was found to promote the penetration of toxoplasma parasites into HeLa cells. The RNIU values found when 1 mg. hyaluronidase per ml. was added to the suspending media were usually about the double of those obtained in tests without the enzyme. The effect of 0.01 mg. hyaluronidase corresponded to that of about 1 mg. lysozyme. When lysozyme and hyaluronidase were used together, a synergistic effect was noted (Table IV). Thus with the combination of 0 05 mg. of lysozyme and TABLE IV.-The Effect of Hyaluronidase, Used Alone or in Combination with Lysozyme, on the Penetration of Toxoplassma into HeLa Cells Compounds tested RNIU Lysozyme (0 5 mg./ml.) . 71*9 Hyaluronidase (05 mg. /ml.). 102 - 6 Lysozyme (05 mg./ml.) + Hyaluronidase (0 005 mg./ml.) . 73-3 Lysozyme (U 05 mg./ml.) + Hyaluronidase (0 05 mg./ml.) 125-7 Lysozyme (0 005 mg./ml.) + Hyaluronidase (0 05 mg./ml.) 87 * 9 Control. (No additive) . 49 9 hyaluronidase respectively, a considerably larger number of parasites were found to penetrate the host cells than if each enzyme had been used separately in a concentration 10 times higher. Table V lists the results of an experiment where hyaluronic acid was added to the parasite suspension at a concentration of 1 mg./ml. ofthe inoculated suspension. The acid was also used mixed with hyaluronidase, 0-1 mg./ml., or lysozyme, 1 mg./ml. Hyaluronic acid inhibited the effect of hyaluronidase as well as that of PENETRATION OF TOXOPLASMA INTO CULTURED CELLS 193 TABLE V.-Inhibition by Hyaluronic Acid of the Penetration-promoting Effect of Lysozyme and Hyaluronidase Compounds tested RNIU Hyaluronidase (O 1 mg./ml.) . 98* 6 Hyaluronidase (0 1 mg.n/ml.) + hyaluronic acid (1 mg.//ml.) . 614 Lysozyme (1 mg./ml.) . 70 0 Lysozyme (1 mg./ml.) + hyaluronic acid (1 mg./ml.) .
Recommended publications
  • Epidemiology of Mucopolysaccharidoses Update
    diagnostics Review Epidemiology of Mucopolysaccharidoses Update Betul Celik 1,2 , Saori C. Tomatsu 2 , Shunji Tomatsu 1 and Shaukat A. Khan 1,* 1 Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; [email protected] (B.C.); [email protected] (S.T.) 2 Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA; [email protected] * Correspondence: [email protected]; Tel.: +302-298-7335; Fax: +302-651-6888 Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a lysosomal enzyme deficiency or malfunction, which leads to the accumulation of glycosaminoglycans in tissues and organs. If not treated at an early stage, patients have various health problems, affecting their quality of life and life-span. Two therapeutic options for MPS are widely used in practice: enzyme replacement therapy and hematopoietic stem cell transplantation. However, early diagnosis of MPS is crucial, as treatment may be too late to reverse or ameliorate the disease progress. It has been noted that the prevalence of MPS and each subtype varies based on geographic regions and/or ethnic background. Each type of MPS is caused by a wide range of the mutational spectrum, mainly missense mutations. Some mutations were derived from the common founder effect. In the previous study, Khan et al. 2018 have reported the epidemiology of MPS from 22 countries and 16 regions. In this study, we aimed to update the prevalence of MPS across the world. We have collected and investigated 189 publications related to the prevalence of MPS via PubMed as of December 2020. In total, data from 33 countries and 23 regions were compiled and analyzed.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • 12MS6741 BQ Vol 8:Layout 1 8/13/12 2:10 PM Page 1
    12MS6741_BQ_Vol_8:Layout 1 8/13/12 2:10 PM Page 1 BioTherapeutics B Quarterly Volume 8/Summer 2012 Diagnostic and Pharmaceutical News for You and Your Medical Practice $4.95 Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News 12MS6741_BQ_Vol_8:Layout 1 8/13/12 2:10 PM Page 2 Choose the Only FDA-approved Hyaluronidase Synthesized by a Recombinant Process OTHER clinically utilized hyaluronidase productscts contain cattle or sheep testes-derived hyaluronidase Hylenex® recombinant (hyaluronidase human injection) is a Safe, Effective and Low Cost Option* • Hylenex recombinant is: – the ONLY recombinant human hyaluronidase available and – the lowest priced FDA-approved hyaluronidase available.* Hylenex® Vitrase® Wydase® Hydase Amphadase® Compounded recombinant Not Since Not Since Not Since Available for Use YES YES 1999 2008 2010 YES FDA-approved YES YES YES YES YES NO FDA-regulated Manufacturing YES YES Not Currently Not Currently Not Currently NO (cGMP**) Made Made Made Recombinant Sheep Cattle Cattle Cattle Cattle Source of Active Ingredient Human Testes Testes Testes Testes Testes Units/mL 150 200 150 150 150 150 *Cost comparison based on published Wholesale Acquisition Cost per single-use vial comparing FDA-approved available products. Red Book March 2012. Price comparison is not indicative of fi nal customer price and is not intended to be a comparison of safety or effi cacy of drugs. **cGMP= Current Good Manufacturing Practices See Important Safety Information and Brief Summary of Full Prescribing Information. BioTherapeutics
    [Show full text]
  • Label, Multicenter, Single Arm Study in Fifty-One (51) Patients
    NDA 21-859/S-009 Page 3 HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypersensitivity (4) _______________ _______________ These highlights do not include all the information needed to use WARNINGS AND PRECAUTIONS HYLENEX recombinant safely and effectively. See full prescribing • Spread of Localized Infection. (5.1) information for HYLENEX recombinant. • Ocular Damage. (5.2) • Enzyme Inactivation with Intravenous Administration. (5.3) ____________________ ____________________ HYLENEX recombinant (hyaluronidase human injection) ADVERSE REACTIONS Initial U.S. Approval: 2005 • Allergic and anaphylactic-like reactions have been reported, rarely (6) __________________ _________________ INDICATIONS AND USAGE To report SUSPECTED ADVERSE REACTIONS, contact Halozyme HYLENEX recombinant is a tissue permeability modifier indicated as an Therapeutics, Inc. at 1-877-877-1679 or FDA at 1-800-FDA-1088 or adjuvant www.fda.gov/medwatch. • ____________________ ____________________ in subcutaneous fluid administration for achieving hydration (1.1) DRUG INTERACTIONS • to increase the dispersion and absorption of other injected drugs (1.2) • Furosemide, the benzodiazepines and phenytoin are incompatible with • in subcutaneous urography for improving resorption of radiopaque hyaluronidase (7.1) agents (1.3) • _______________ ______________ Hyaluronidase should not be used to enhance the absorption and DOSAGE AND ADMINISTRATION dispersion of dopamine and/or alpha agonist drugs (7.2) • Subcutaneous fluid administration: • Local anesthetics: Hyaluronidase hastens onset
    [Show full text]
  • Enzymes for Cell Dissociation and Lysis
    Issue 2, 2006 FOR LIFE SCIENCE RESEARCH DETACHMENT OF CULTURED CELLS LYSIS AND PROTOPLAST PREPARATION OF: Yeast Bacteria Plant Cells PERMEABILIZATION OF MAMMALIAN CELLS MITOCHONDRIA ISOLATION Schematic representation of plant and bacterial cell wall structure. Foreground: Plant cell wall structure Background: Bacterial cell wall structure Enzymes for Cell Dissociation and Lysis sigma-aldrich.com The Sigma Aldrich Web site offers several new tools to help fuel your metabolomics and nutrition research FOR LIFE SCIENCE RESEARCH Issue 2, 2006 Sigma-Aldrich Corporation 3050 Spruce Avenue St. Louis, MO 63103 Table of Contents The new Metabolomics Resource Center at: Enzymes for Cell Dissociation and Lysis sigma-aldrich.com/metpath Sigma-Aldrich is proud of our continuing alliance with the Enzymes for Cell Detachment International Union of Biochemistry and Molecular Biology. Together and Tissue Dissociation Collagenase ..........................................................1 we produce, animate and publish the Nicholson Metabolic Pathway Hyaluronidase ...................................................... 7 Charts, created and continually updated by Dr. Donald Nicholson. DNase ................................................................. 8 These classic resources can be downloaded from the Sigma-Aldrich Elastase ............................................................... 9 Web site as PDF or GIF files at no charge. This site also features our Papain ................................................................10 Protease Type XIV
    [Show full text]
  • Separation of Oligosaccharides from Lotus Seeds Via Medium-Pressure Liquid Chromatography Coupled with ELSD and DAD
    www.nature.com/scientificreports OPEN Separation of Oligosaccharides from Lotus Seeds via Medium- pressure Liquid Chromatography Received: 20 September 2016 Accepted: 06 February 2017 Coupled with ELSD and DAD Published: 09 March 2017 Xu Lu1,2,3, Zhichang Zheng1, Song Miao2, Huang Li1, Zebin Guo1,3, Yi Zhang1,3, Yafeng Zheng1,3, Baodong Zheng1,3 & Jianbo Xiao1,4 Lotus seeds were identified by the Ministry of Public Health of China as both food and medicine. One general function of lotus seeds is to improve intestinal health. However, to date, studies evaluating the relationship between bioactive compounds in lotus seeds and the physiological activity of the intestine are limited. In the present study, by using medium pressure liquid chromatography coupled with evaporative light-scattering detector and diode-array detector, five oligosaccharides were isolated and their structures were further characterized by electrospray ionization-mass spectrometry and gas chromatography-mass spectrometry. In vitro testing determined that LOS3-1 and LOS4 elicited relatively good proliferative effects onLactobacillus delbrueckii subsp. bulgaricus. These results indicated a structure-function relationship between the physiological activity of oligosaccharides in lotus seeds and the number of probiotics applied, thus providing room for improvement of this particular feature. Intestinal probiotics may potentially become a new effective drug target for the regulation of immunity. Lotus seeds are mature seeds of Nelumbo nucifera Gaertn and are so far the oldest plant seeds currently known. In China, lotus seeds have been traditionally used as both pharmaceutical and food resource. Bioactive ingredi- ents such as water-soluble carbohydrates, alkaloids, flavonoids, and superoxide dismutase (SOD) render various bioactivities to lotus seeds that regulate intestinal and stomach functions, prevent oxidation, lower blood glucose, and boost immunity.
    [Show full text]
  • Mutagenesis of Human Alpha-Galactosidase a for the Treatment of Fabry Disease
    City University of New York (CUNY) CUNY Academic Works All Dissertations, Theses, and Capstone Projects Dissertations, Theses, and Capstone Projects 9-2017 Mutagenesis of Human Alpha-Galactosidase A for the Treatment of Fabry Disease Erin Stokes The Graduate Center, City University of New York How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/gc_etds/2338 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] CITY COLLEGE, CITY UNIVERSITY OF NEW YORK MUTAGENESIS OF HUMAN ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE By Erin Stokes A dissertation submitted to the Graduate Faculty in Biochemistry in partial fulfillment of the requirement for the degree of Doctor of Philosophy, The City University of New York 2017 ©2017 Erin Stokes All rights reserved ii Mutagenesis of Human α-Galactosidase A for the Treatment of Fabry Disease By Erin Stokes This manuscript has been read and accepted for the Graduate Faculty Biochemistry in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy. ______________________ David H. Calhoun Date Chair of Examining Committee ______________________ Richard Magliozzo Date Executive Officer Supervisory Committee: Haiping Cheng (Lehman College, CUNY) M. Lane Gilchrist (City College of New York, CUNY) Emanuel Goldman (New Jersey Medical School, Rutgers) Kevin Ryan (City College of New York, CUNY) THE CITY UNIVERSITY OF NEW YORK iii Abstract Mutagenesis of Human α-Galactosidase A for the Treatment of Fabry Disease By Erin Stokes Advisor: Dr.
    [Show full text]
  • Modelling Reactions Catalysed by Carbohydrate-Active Enzymes
    bioRxiv preprint doi: https://doi.org/10.1101/008615; this version posted November 12, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Modeling Reactions Catalyzed by Carbohydrate-Active Enzymes Önder Kartal, Oliver Ebenhöh November 12, 2014 Abstract Carbohydrate polymers are ubiquitous in biological systems and their roles are highly diverse, ranging from energy storage over mechanical sta- bilisation to mediating cell-cell or cell-protein interactions. The functional diversity is mirrored by a chemical diversity that results from the high flexi- bility of how different sugar monomers can be arranged into linear, branched or cyclic polymeric structures. Mathematical models describing biochemi- cal processes on polymers are faced with various difficulties. First, polymer- active enzymes are often specific to some local configuration within the poly- mer but are indifferent to other features. That is they are potentially active on a large variety of different chemical compounds, meaning that polymers of different size and structure simultaneously compete for enzymes. Second, especially large polymers interact with each other and form water-insoluble phases that restrict or exclude the formation of enzyme-substrate complexes. This heterogeneity of the reaction system has to be taken into account by explicitly considering processes at the, often complex, surface of the poly- mer matrix. We review recent approaches to theoretically describe polymer biochemical systems. All attempts address a particular challenge, which we discuss in more detail.
    [Show full text]
  • Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action
    Chem. Rev. 2006, 106, 818−839 818 Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action Robert Stern† and Mark J. Jedrzejas*,‡ Children’s Hospital Oakland Research Institute, Oakland, California 94609, and Department of Pathology and UCSF Comprehensive Cancer Center, School of Medicine, University of California, San Francisco, California 94143-0511 Received April 26, 2005 Contents 8. Bacterial Hyaluronidases: Their Structure and 833 Mechanism of Action 1. Introduction 818 8.1. Polymeric Glycan-Binding Cleft: A Common 833 1.1. Overview of the Hyaluronidases 818 Feature of the Hyaluronidases and Other 1.2. Assays for Hyaluronidase Activity 820 Glycan-Degrading Enzymes 1.3. Eukaryote Hydrolase-Type of Hyaluronidases 820 8.2. Domain Structure Bacterial Hyaluronidases 834 1.4. Prokaryote Eliminase-Type of Hyaluronidases 820 8.3. Mechanism of Hyaluronan Degradation by 834 1.5. endo-â-Glucuronidase-Type of 820 Bacterial Hyaluronan Lyases Hyaluronidases 8.4. Streptomyces hyalurolyticus Hyaluronan 836 1.6. Fungal Hyaluronidases 820 Lyase 2. Hyaluronan as a Substrate for Catalysis 820 9. Summary 836 3. Properties of the Hyaluronidases 821 9.1. Conclusions 836 3.1. Designation of Hyaluronidases as a Class 821 9.2. Future Directions 836 within the Glycosidase Families of Enzymes 10. Abbreviations 837 3.2. The Term "Hyaluronidase" Is a Misnomer 822 11. Acknowledgments 837 3.3. Evolution of Hyaluronidases Can Be 822 12. Supporting Information 837 Postulated from Their Substrate Specificity 13. References 837 3.4. Digestion Products of Human and Bacterial 823 Hyaluronidase Catalysis 4. Identification of Mechanism of Hyaluronan 823 1. Introduction Degradation by Vertebrate-like Hyaluronidases 4.1. Catalytic Mechanism and Its Importance 823 1.1.
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Cazymes Catalogue 2021
    cazymes 2021 Visit the Online Store www.nzytech.com Newsletter NZYWallet Instantaneous Quotes Subscribe our newsletter to receive NZYWallet is a prepaid account Do you need an urgent quote? Just awesome news and promotions. that oers the flexibility you need add your products to Cart, proceed to focus on your research. With to Checkout, select quote and it’s NZYWallet you can buy any done! product from our Online Store, check your up-to-date balance and track your latest orders. Contact our customer service at [email protected] or your local sales representative for more information. Follow us: 2021 NZYTech NZYTech 2 Visit the Online Store www.nzytech.com Newsletter NZYWallet Instantaneous Quotes Subscribe our newsletter to receive NZYWallet is a prepaid account Do you need an urgent quote? Just awesome news and promotions. that oers the flexibility you need add your products to Cart, proceed to focus on your research. With to Checkout, select quote and it’s NZYWallet you can buy any done! product from our Online Store, check your up-to-date balance and track your latest orders. Contact our customer service at [email protected] or your local sales representative for more information. Follow us: cazymes 3 4 2021 NZYTech NZYTech OVERVIEW 8 GLYCOSIDE HYDROLASES 10 Acetylgalactosaminidases Acetylglucosaminidases Agarases Amylases @ a glance Amylomaltases Arabinanases Arabinofuranosidases Arabinopyranosidases Arabinoxylanases Carrageenases Cellobiohydrolases Cellodextrinases Cellulases Chitinases Chitosanases Dextranases Fructanases Fructofuranosidases
    [Show full text]
  • Protein List
    Protein Accession Protein Id Protein Name P11171 41 Protein 4.
    [Show full text]